Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Li, K; Fichna, J; Schicho, R; Saur, D; Bashashati, M; Mackie, K; Li, Y; Zimmer, A; Göke, B; Sharkey, KA; Storr, M.
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.
Neuropharmacology. 2013; 71(3):255-263
Doi: 10.1016/j.neuropharm.2013.03.029
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Schicho Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective: The G protein-coupled receptor 55 (GPR55) is a novel cannabinoid (CB) receptor, whose role in the gastrointestinal (GI) tract remains unknown. Here we studied the significance of GPR55 in the regulation of GI motility. Design: GPR55 mRNA and protein expression were measured by RT-PCR and immunohistochemistry. The effects of the GPR55 agonist O-1602 and a selective antagonist cannabidiol (CBD) were studied in vitro and in vivo and compared to a non-selective cannabinoid receptor agonist WIN55,212-2. CB1/2-/- and GPR55(-/-) mice were employed to identify the receptors involved. Results: GPR55 was localized on myenteric neurons in mouse and human colon. O-1602 concentration-dependently reduced evoked contractions in muscle strips from the colon (similar to 60%) and weakly (similar to 25%) from the ileum. These effects were reversed by CBD, but not by CB1 or CB2 receptor antagonists. I.p. and i.c.v. injections of O-1602 slowed whole gut transit and colonic bead expulsion; these effects were absent in GPR55-/- mice. WIN55,212-2 slowed whole gut transit effects, which were counteracted in the presence of a CB1 antagonist AM251. WIN55,212-2, but not O-1602 delayed gastric emptying and small intestinal transit. Locomotion, as a marker for central sedation, was reduced following WIN55,212-2, but not O-1602 treatment. Conclusion: GPR55 is strongly expressed on myenteric neurons of the colon and it is selectively involved in the regulation of colonic motility. Since activation of GPR55 receptors is not associated with central sedation, the GPR55 receptor may serve as a future target for the treatment of colonic motility disorders. (C) 2013 Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Cannabidiol - analogs & derivatives
- Cannabinoid Receptor Antagonists - pharmacology
- Cannabinoids - pharmacology
- Colon - cytology
- Colonic Diseases, Functional - drug therapy
- Gastrointestinal Motility - drug effects
- Gene Expression Regulation -
- Humans -
- Male -
- Mice -
- Mice, Inbred Strains -
- Mice, Knockout -
- Molecular Targeted Therapy -
- Muscle, Smooth - cytology
- Myenteric Plexus - cytology
- Nerve Tissue Proteins - agonists
- Neurons - cytology
- Receptor, Cannabinoid, CB1 - agonists
- Receptor, Cannabinoid, CB2 - agonists
- Receptors, Cannabinoid - chemistry
- Tissue Banks -
- Find related publications in this database (Keywords)
- Cannabidiol
- Cannabinoid
- Colon
- Gastrointestinal motility
- GPR55